Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer

被引:2
|
作者
Jurj, Ancuta [1 ]
Zanoaga, Oana [1 ]
Raduly, Lajos [1 ]
Morhan, Vlad [2 ]
Papi, Zsofia [3 ]
Ciocan, Cristina [1 ]
Pop, Laura-Ancuta [1 ]
Berindan-Neagoe, Ioana [1 ]
Braicu, Cornelia [1 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom, Biomed & Translat Med, Cluj Napoca 400347, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Cluj Napoca 400347, Romania
[3] Univ Szeged, Fac Med, H-6720 Szeged, Hungary
关键词
miR-29b-3p inhibitor; triple-negative breast cancer; miRNA; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; CELLS; EXPRESSION; GROWTH;
D O I
10.3390/ijms24055048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lack of estrogen or progesterone receptors and absence of HER2 amplification/overexpression in triple-negative breast cancer (TNBC) restricts therapeutic options used in clinical management. MicroRNAs (miRNAs) are small, non-coding transcripts which affect important cellular mechanisms by regulating gene expression at the post-transcriptional level. Among this class, attention was focused on miR-29b-3p with a high profile in TNBC and correlated with the overall survival rates, as TCGA data revealed. This study aims to investigate the implication of the miR-29b-3p inhibitor in TNBC cell lines by identifying a potential therapeutic transcript, improving the clinical outcomes of this disease. The experiments were performed on two TNBC cell lines (MDA-MB-231 and BT549) as in vitro models. An established dose of 50 nM was used for all functional assays performed on the miR-29b-3p inhibitor. A decreased level of miR-29b-3p determined a significant reduction in cell proliferation and colony-forming capacity. At the same time, the changes occurring at the molecular and cellular levels were highlighted. We observed that, when inhibiting the expression level of miR-29b-3p, processes such as apoptosis and autophagy were activated. Further, microarray data revealed that the miRNA expression pattern was altered after miR-29b-3p inhibition, pointing out 8 overexpressed and 11 downregulated miRNAs specific for BT549 cells and 33 upregulated and 10 downregulated miRNAs that were specific for MDA-MB-231 cells. As a common signature for both cell lines, three transcripts were observed, two downregulated, miR-29b-3p and miR-29a, and one upregulated, miR-1229-5p. According to DIANA miRPath, the main predicted targets are related to ECM (extracellular matrix) receptor interaction and TP53 signaling. An additional validation step through qRT-PCR was performed, which showed an upregulation of MCL1 and TGFB1. By inhibiting the expression level of miR-29b-3p, it was shown that complex regulatory pathways targeted this transcript in TNBC cells.
引用
下载
收藏
页数:16
相关论文
共 50 条
  • [21] Therapeutic Strategies for Triple-Negative Breast Cancer
    Tan, Antoinette R.
    Swain, Sandra M.
    CANCER JOURNAL, 2008, 14 (06): : 343 - 351
  • [22] Triple-negative breast cancer: therapeutic options
    Cleator, Susan
    Heller, Wolfgang
    Coombes, R. Charles
    LANCET ONCOLOGY, 2007, 8 (03): : 235 - 244
  • [23] Biological Subtypes of Triple-Negative Breast Cancer
    Hubalek, Michael
    Czech, Theresa
    Mueller, Hannes
    BREAST CARE, 2017, 12 (01) : 8 - 14
  • [24] SIGNIFICANCE OF C-MET AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
    Kashiwagi, S.
    Yashiro, M.
    Aomatsu, N.
    Kawajiri, H.
    Takashima, T.
    Onoda, N.
    Ishikawa, T.
    Hirakawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 84 - 84
  • [25] Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers
    Soung, Young Hwa
    Chung, Heesung
    Yan, Cecilia
    Fesler, Andrew
    Kim, Hyungjin
    Oh, Eok-Soo
    Ju, Jingfang
    Chung, Jun
    CANCERS, 2020, 12 (08) : 1 - 16
  • [26] Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer
    Sayed-Ahmed, Mohamed Mohamed
    Hafez, Mohamed Mahmoud
    Al-Shabanah, Othman Abdualla
    Al-Rejaie, Salim Salih
    Aleisa, Abdulaziz Mohamed
    Al-Yahya, Abdulaziz Abdulrhman
    Alsheikh, Abdulmalik
    Al Diab, Abdurrahman Ibrahim
    Al-Akeely, Mohammad Hamad
    TUMORI JOURNAL, 2013, 99 (04): : 545 - 554
  • [27] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
    Kumar, Hitesh
    Gupta, N. Vishal
    Jain, Rupshee
    Madhunapantula, Subbarao V.
    Babu, C. Saravana
    Kesharwani, Siddharth S.
    Dey, Surajit
    Jain, Vikas
    JOURNAL OF ADVANCED RESEARCH, 2023, 54 : 271 - 292
  • [28] A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status
    Shen, Songjie
    Sun, Qiang
    Liang, Zhiyong
    Cui, Xiaojiang
    Ren, Xinyu
    Chen, Huan
    Zhang, Xiao
    Zhou, Yidong
    PLOS ONE, 2014, 9 (06):
  • [29] Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer
    Chen, Luxi
    Long, Chao
    Nguyen, Jennifer
    Kumar, Dhiraj
    Lee, Jiyong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (03) : 420 - 424
  • [30] Significance of the vimentin expression in triple-negative breast cancer
    Yamashita, Nami
    Tokunaga, Eriko
    Kitao, Hiroyuki
    Tanaka, Kimihiro
    Taketani, Kenji
    Saeki, Hiroshi
    Aishima, Shinichi
    Oki, Eiji
    Morita, Masaru
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)